#为什么进口猕猴桃能比国产贵10倍#
Many people with sickle-cell anemia—and the particular genetic mutation that causes it—die at an early age. While the notion of “survival of the fittest” may suggest that people suffering from this disease have a low survival rate and therefore the disease will become less common, this is not the case. Despite the negative evolutionary effects associated with this genetic mutation, the sickle-cell gene remains relatively common among people of African descent. Why is this? The explanation is illustrated with the following scenario.
Many people with sickle-cell anemia—and the particular genetic mutation that causes it—die at an early age. While the notion of “survival of the fittest” may suggest that people suffering from this disease have a low survival rate and therefore the disease will become less common, this is not the case. Despite the negative evolutionary effects associated with this genetic mutation, the sickle-cell gene remains relatively common among people of African descent. Why is this? The explanation is illustrated with the following scenario.
Gene Maternity 简因孕产是中国孕产期运动引领品牌!专注于孕产训练技术研发/培训传播的匠心学府!
国内专注于孕产期运动的专业研发、培训机构，授课导师均拥有丰富的专业的职业及授课经验，或拥有自己的孕产主题工作室或专业实体。
课程体系引进自世界上孕期运动最发达的北欧芬兰，涵盖备孕、孕期、产后，完整且科学。
MEGA BASE健身私教伙伴们，已完成简因孕产导师培训认证，孕产前后的准辣妈们准备好和我们一起，迎接新生命的同时也完成自己的进阶吧！
#孕产知识#孕产期 #孕产运动
#孕产[超话]# https://t.cn/z82D15Z
国内专注于孕产期运动的专业研发、培训机构，授课导师均拥有丰富的专业的职业及授课经验，或拥有自己的孕产主题工作室或专业实体。
课程体系引进自世界上孕期运动最发达的北欧芬兰，涵盖备孕、孕期、产后，完整且科学。
MEGA BASE健身私教伙伴们，已完成简因孕产导师培训认证，孕产前后的准辣妈们准备好和我们一起，迎接新生命的同时也完成自己的进阶吧！
#孕产知识#孕产期 #孕产运动
#孕产[超话]# https://t.cn/z82D15Z
美国FDA、NIH以及15家机构（包括10家药企和5个非盈利性组织）将合作研究开发基因疗法药物治疗罕见病。
这15家机构名单如下：
1.Biogen Inc., Cambridge, Massachusetts;
2.Janssen Research & Development, LLC, Raritan, New Jersey;
3.Novartis Institutes for BioMedical Research, Cambridge, Massachusetts;
4.Pfizer Inc., New York, New York;
5.REGENXBIO Inc., Rockville, Maryland.;
6.Spark Therapeutics, Philadelphia, Pennsylvania;
7.Takeda Pharmaceutical Company Limited, Deerfield, Illinois;
8.Taysha Gene Therapies, Dallas, Texas;
9.Thermo Fisher Scientific Inc., Waltham, Massachusetts;
10.Ultragenyx Pharmaceutical, Novato, California.
11.The Alliance for Regenerative Medicine (ARM), Washington, D.C.;
12.The American Society of Gene and Cell Therapy, Milwaukee, Wisconsin;
13.CureDuchenne, Newport Beach, California;
14.National Organization for Rare Disorders (NORD), Quincy, Massachusetts;
15.The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL), Newark, Delaware.
美国约有2500万到3000万人患有各类罕见病。人类总共约有7000种罕见病，其中只有两种遗传性罕见病目前已有FDA批准的基因疗法药物进行治疗。
详见：https://t.cn/A6xy477L
FDA, NIH, and 15 private organizations join forces to increase effective gene therapies for rare diseases
For Immediate Release:
October 27, 2021
The U.S. Food and Drug Administration, the National Institutes of Health, 10 pharmaceutical companies and five non-profit organizations have partnered to accelerate development of gene therapies for the 30 million Americans who suffer from a rare disease. While there are approximately 7,000 rare diseases, only two heritable diseases currently have FDA-approved gene therapies. The newly launched Bespoke Gene Therapy Consortium (BGTC), part of the NIH Accelerating Medicines Partnership (AMP) program and project-managed by the Foundation for the National Institutes of Health (FNIH), aims to optimize and streamline the gene therapy development process to help fill the unmet medical needs of people with rare diseases.
这15家机构名单如下：
1.Biogen Inc., Cambridge, Massachusetts;
2.Janssen Research & Development, LLC, Raritan, New Jersey;
3.Novartis Institutes for BioMedical Research, Cambridge, Massachusetts;
4.Pfizer Inc., New York, New York;
5.REGENXBIO Inc., Rockville, Maryland.;
6.Spark Therapeutics, Philadelphia, Pennsylvania;
7.Takeda Pharmaceutical Company Limited, Deerfield, Illinois;
8.Taysha Gene Therapies, Dallas, Texas;
9.Thermo Fisher Scientific Inc., Waltham, Massachusetts;
10.Ultragenyx Pharmaceutical, Novato, California.
11.The Alliance for Regenerative Medicine (ARM), Washington, D.C.;
12.The American Society of Gene and Cell Therapy, Milwaukee, Wisconsin;
13.CureDuchenne, Newport Beach, California;
14.National Organization for Rare Disorders (NORD), Quincy, Massachusetts;
15.The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL), Newark, Delaware.
美国约有2500万到3000万人患有各类罕见病。人类总共约有7000种罕见病，其中只有两种遗传性罕见病目前已有FDA批准的基因疗法药物进行治疗。
详见：https://t.cn/A6xy477L
FDA, NIH, and 15 private organizations join forces to increase effective gene therapies for rare diseases
For Immediate Release:
October 27, 2021
The U.S. Food and Drug Administration, the National Institutes of Health, 10 pharmaceutical companies and five non-profit organizations have partnered to accelerate development of gene therapies for the 30 million Americans who suffer from a rare disease. While there are approximately 7,000 rare diseases, only two heritable diseases currently have FDA-approved gene therapies. The newly launched Bespoke Gene Therapy Consortium (BGTC), part of the NIH Accelerating Medicines Partnership (AMP) program and project-managed by the Foundation for the National Institutes of Health (FNIH), aims to optimize and streamline the gene therapy development process to help fill the unmet medical needs of people with rare diseases.
✋热门推荐